1. Scrip
  2. >>Business

Servier’s Kamoun On Breaking Brain Cancer Barriers By Harnessing Cancer Metabolism

 
• By Ayisha Sharma

The private French firm’s new global head of R&D oncology spoke with Scrip about its two-pronged oncology strategy and its high hopes for the advanced glioma candidate, vorasidenib, which may improve upon Tibsovo.  

Multicolor image of tumor cells under microscope
Several Firms Have Struggled To Develop Successful Glioma Drugs • Source: Shutterstock

Les Laboratoires Servier is determined to tackle the challenging glioma space with a cancer metabolism-based asset gained through its acquisition of Agios Pharmaceuticals, Inc.’ oncology portfolio, new executive Walid Kamoun told Scrip.

Kamoun was appointed global head of the French firm’s R&D Oncology in April, bringing 20 years of industry experience. He...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.